methyl (5R)-2-[(1S)-1-(3-nitrophenyl)propyl]-3-oxo-5-(2-phenylethyl)-5-[(4-phenylphenoxy)methoxy]octanoate | 215317-19-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: methyl (5R)-2-[(1S)-1-(3-nitrophenyl)propyl]-3-oxo-5-(2-phenylethyl)-5-[(4-phenylphenoxy)methoxy]octanoate
• CAS: 215317-19-4
• 化学式: C₃₉H₄₃NO₇
• 分子量: 637.773
• InChiKey: NQHOCUSTYHHGRC-XLUUUIAZSA-N

物化性质

• 沸点：
  758.3±60.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  9.3
• 重原子数：
  47
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  108
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl (5R)-2-[(1S)-1-(3-nitrophenyl)propyl]-3-oxo-5-(2-phenylethyl)-5-[(4-phenylphenoxy)methoxy]octanoate 在 palladium on activated charcoal sodium hydroxide 、 硫酸 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， -30.0~23.0 ℃ 、344.73 kPa 条件下， 反应 112.0h， 生成 替拉那韦
  参考文献：
  名称：

  A Convergent, Scalable Synthesis of HIV Protease Inhibitor PNU-140690

  摘要：

  PNU-140690, an inhibitor of the HIV protease enzyme undergoing clinical evalution as a chemotherapeutic agent for treatment of AIDS, was synthesized by a convergent approach amenable to large-scale preparation in a pilot plant environment. The key step is the aldol addition of nitroaromatic ester (+)-8 to aldehyde 19e. The two stereocenters present in the target molecule were each set independently by resolution of enantiomers. Intermediates along the synthetic routes were chosen to maximize opportunities for isolation and purification by crystallization.

  DOI：

  10.1021/jo9809229
• 作为产物：
  描述：

  methyl (5R)-3-hydroxy-2-[(1S)-1-(3-nitrophenyl)propyl]-5-(2-phenylethyl)-5-[(4-phenylphenoxy)methoxy]octanoate 在 florisil 、 sodium acetate 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以99.2%的产率得到methyl (5R)-2-[(1S)-1-(3-nitrophenyl)propyl]-3-oxo-5-(2-phenylethyl)-5-[(4-phenylphenoxy)methoxy]octanoate
  参考文献：
  名称：

  A Convergent, Scalable Synthesis of HIV Protease Inhibitor PNU-140690

  摘要：

  PNU-140690, an inhibitor of the HIV protease enzyme undergoing clinical evalution as a chemotherapeutic agent for treatment of AIDS, was synthesized by a convergent approach amenable to large-scale preparation in a pilot plant environment. The key step is the aldol addition of nitroaromatic ester (+)-8 to aldehyde 19e. The two stereocenters present in the target molecule were each set independently by resolution of enantiomers. Intermediates along the synthetic routes were chosen to maximize opportunities for isolation and purification by crystallization.

  DOI：

  10.1021/jo9809229

文献信息

• J. Org. Chem. 1998, 63, 7348-7356
  作者：

  DOI：——

  日期：——
• DEUTERIUM-ENRICHED TIPRANAVIR
  申请人：Czarnik Anthony W.

  公开号：US20090062346A1

  公开（公告）日：2009-03-05

  The present application describes deuterium-enriched tipranavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
• A Convergent, Scalable Synthesis of HIV Protease Inhibitor PNU-140690
  作者：Kristina S. Fors、James R. Gage、Richard F. Heier、Robert C. Kelly、William R. Perrault、Nancy Wicnienski

  DOI：10.1021/jo9809229

  日期：1998.10.1

  PNU-140690, an inhibitor of the HIV protease enzyme undergoing clinical evalution as a chemotherapeutic agent for treatment of AIDS, was synthesized by a convergent approach amenable to large-scale preparation in a pilot plant environment. The key step is the aldol addition of nitroaromatic ester (+)-8 to aldehyde 19e. The two stereocenters present in the target molecule were each set independently by resolution of enantiomers. Intermediates along the synthetic routes were chosen to maximize opportunities for isolation and purification by crystallization.